menu

Optimizing LDL-C Management in the Post-MI Patient

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Optimizing LDL-C Management in the Post-MI Patient

close
0.50 credits
30 minutes
Optimizing LDL-C Management in the Post-MI Patient
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Cholesterol guidelines recommend nonstatin, LDL-C-lowering therapies in very high risk ASCVD patients if LDL-C goals are not achieved (ESC/EAS dyslipidemia guideline) or if LDL-C is above a specific threshold of 70 mg/dL (AHA/ACC cholesterol guideline).  Unfortunately, a substantial number of patients with ASCVD do not achieve LDL-C targets, and nonstatin, LDL-C-lowering therapies are underutilized.  Therefore, patients such as those who have experienced an acute coronary syndrome (ACS) remain at increased risk for another major cardiovascular event.  Patients with a recent ACS are especially vulnerable to a recurrent cardiovascular event.  Nonstatin, LDL-C-lowering therapy with PCSK9 inhibitors and ezetimibe has demonstrated reductions in cardiovascular risk after an ACS.  PCSK9 inhibitors have demonstrated robust LDL-C lowering to very low LDL-C levels, with no increase in adverse safety events and with additional cardiovascular risk reduction.  Analyses of cardiovascular outcome trial data with PCSK9 inhibition have indicated particularly potent cardiovascular risk reduction in patients with a recent ACS; utilizing PCSK9 inhibitors in these patients enables clinicians to greatly improve their patients’ clinical outcomes. Significant LDL-C reductions, rapid LDL-C goal attainment, and safety have been observed in very early (in-hospital) use of PCSK9 inhibitors.  In this educational initiative, lipid expert Dr. Marc Sabatine will discuss guideline recommendations for using nonstatin, LDL-C-lowering therapies, and clinical evidence for early, intensive LDL-C reduction in ACS patients to reduce cardiovascular risk.

  • Disclosure of Conflicts of Interest

    It is the policy of Voxmedia to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose any significant financial, other interest or relationship (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only then may faculty receive approval to participate, and are expected to contribute evidence-based material and information. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis etc. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will make the required disclosure to the audience.  It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation. In addition, presenters must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

  • Target Audience

    This educational activity is intended for clinicians who manage patients with cardiovascular disease.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Explain current guideline recommendations and treatment patterns for patients with ASCVD and elevated LDL-C.
    2. Indicate the increased ASCVD risk for post-MI patients within the first year of the index event.
    3. Interpret data with PCSK9 inhibitors in patients with recent MI.
  • Accreditation and Credit Designation Statements

    Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Voxmedia LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
    The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an educational donation provided by Amgen.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Cholesterol guidelines recommend nonstatin, LDL-C-lowering therapies in very high risk ASCVD patients if LDL-C goals are not achieved (ESC/EAS dyslipidemia guideline) or if LDL-C is above a specific threshold of 70 mg/dL (AHA/ACC cholesterol guideline).  Unfortunately, a substantial number of patients with ASCVD do not achieve LDL-C targets, and nonstatin, LDL-C-lowering therapies are underutilized.  Therefore, patients such as those who have experienced an acute coronary syndrome (ACS) remain at increased risk for another major cardiovascular event.  Patients with a recent ACS are especially vulnerable to a recurrent cardiovascular event.  Nonstatin, LDL-C-lowering therapy with PCSK9 inhibitors and ezetimibe has demonstrated reductions in cardiovascular risk after an ACS.  PCSK9 inhibitors have demonstrated robust LDL-C lowering to very low LDL-C levels, with no increase in adverse safety events and with additional cardiovascular risk reduction.  Analyses of cardiovascular outcome trial data with PCSK9 inhibition have indicated particularly potent cardiovascular risk reduction in patients with a recent ACS; utilizing PCSK9 inhibitors in these patients enables clinicians to greatly improve their patients’ clinical outcomes. Significant LDL-C reductions, rapid LDL-C goal attainment, and safety have been observed in very early (in-hospital) use of PCSK9 inhibitors.  In this educational initiative, lipid expert Dr. Marc Sabatine will discuss guideline recommendations for using nonstatin, LDL-C-lowering therapies, and clinical evidence for early, intensive LDL-C reduction in ACS patients to reduce cardiovascular risk.

  • Disclosure of Conflicts of Interest

    It is the policy of Voxmedia to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose any significant financial, other interest or relationship (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only then may faculty receive approval to participate, and are expected to contribute evidence-based material and information. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis etc. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will make the required disclosure to the audience.  It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation. In addition, presenters must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

  • Target Audience

    This educational activity is intended for clinicians who manage patients with cardiovascular disease.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Explain current guideline recommendations and treatment patterns for patients with ASCVD and elevated LDL-C.
    2. Indicate the increased ASCVD risk for post-MI patients within the first year of the index event.
    3. Interpret data with PCSK9 inhibitors in patients with recent MI.
  • Accreditation and Credit Designation Statements

    Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Voxmedia LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
    The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an educational donation provided by Amgen.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 7/27/21